Acción LYTIX LYTIX BIOPHARMA
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Lytix Biopharma

Acciones

LYTIX

NO0010405780

Mercado cerrado - Oslo Bors
Otros sitios de cotización
 16:45:00 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
5,86 NOK 0,00 % Gráfico intradía de Lytix Biopharma +2,45 % +20,58 %
25/04 Lytix Biopharma anuncia la aprobación del estudio de fase II en cáncer de piel (melanoma) en estadio inicial, que representa una importante oportunidad comercial CI
10/04 Lytix Biopharma recaudará hasta 55 millones de coronas noruegas mediante una oferta de acciones MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Correction in the notice of Annual General Meeting in Lytix Biopharma AS
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024
Lytix Biopharma AS: Annual Report for 2023
Lytix Biopharma AS - Share issue pursuant to board authorisation
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity
Lytix Biopharma AS - Preliminary results in the share offering
Lytix Biopharma AS - Last day of the Application Period
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lytix Biopharma presents third quarter 2023 results
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción LYTIX
  4. Noticias Lytix Biopharma
  5. Otros idiomas